What Happens When Pharmaceutical Research Becomes Fully Open-Access

The case for fully open-access pharmaceutical research rests on a specific diagnosis of the current system's failures and a specific theory of how removing information barriers would change the incentive landscape. Both deserve rigorous examination.

The Current System's Structural Failures

The pharmaceutical research system is governed by an intersection of patent law, regulatory requirements, and commercial incentives that has been stable in its basic structure since the Hatch-Waxman Act in the United States (1984) and its equivalents internationally. The system's core logic: private investment in research and development is rewarded by patent exclusivity, typically twenty years from filing, during which the patent holder can charge monopoly prices. At patent expiration, generic manufacturers can produce equivalent drugs at dramatically lower prices.

This system has genuine strengths. It aligns private capital with research output. It has funded the development of drug classes that have transformed medicine — ACE inhibitors, statins, SSRIs, HIV antiretrovirals, targeted oncology therapies. The innovation these drugs represent is real.

But the system also has structural failures that are now well-documented:

First, research orientation bias. The commercial incentive structure directs research toward conditions affecting wealthy populations who can pay patent prices, treatments for chronic conditions requiring lifetime medication, and incremental modifications of existing drugs that extend patent protection without substantially improving therapeutic value. Diseases affecting primarily low-income populations receive a fraction of research investment proportional to their disease burden. The pipeline is shaped by market size, not medical need.

Second, publication bias and data suppression. The All Trials campaign and subsequent research by Ben Goldacre and others has documented extensively that roughly half of all clinical trials are never published. Trials with positive results are published at roughly twice the rate of trials with negative results. Companies routinely conduct multiple trials, publish the successful ones, and archive the failures. This creates a false picture of drug efficacy in the published literature and makes evidence-based prescribing systematically misleading.

Third, pricing disconnected from development cost. The argument that patent prices reflect research and development costs is substantially false as a description of most patented drugs. Drug pricing is determined by what the market will bear — what insurers will pay, what regulatory bodies will accept — not by amortized research costs. The actual cost of developing specific drugs is proprietary information in most cases; companies do not disclose it. Independent estimates vary enormously, partly because companies include marketing, failed compounds, and capital costs in different ways. The claim that current prices are necessary to recoup development investment has been shown to be exaggerated in most documented cases.

Fourth, the neglected disease gap. The WHO estimates that 1.5 billion people suffer from neglected tropical diseases — conditions like sleeping sickness, Chagas disease, leishmaniasis, and lymphatic filariasis that are debilitating and often lethal, but that have not attracted substantial pharmaceutical investment because affected populations cannot pay patent prices. The ten diseases responsible for the greatest global mortality and morbidity do not align with the ten diseases receiving the most pharmaceutical research investment.

What Full Open Access Would Change

"Fully open-access pharmaceutical research" is not a single policy. It is a cluster of related but distinct interventions, each with different effects:

1. Open clinical trial registration and mandatory results publication. This is already partially implemented. The International Clinical Trials Registry Platform and ClinicalTrials.gov require registration of trials prior to initiation, and many journals require registration as a condition of publication. But reporting remains incomplete. A mandatory, enforced full-disclosure regime — where all registered trials must publish full results within a defined period regardless of outcome, with legal penalties for non-compliance — would substantially reduce publication bias.

2. Open access to compound libraries. Pharmaceutical companies maintain proprietary libraries of screened chemical compounds and their biological activity profiles. These represent enormous sunk-cost research investments. Open access to these libraries — possibly through a pool licensing model or through regulatory requirements tied to market access — would allow academic and non-profit researchers to identify candidates for neglected disease research that companies have screened but set aside.

3. Open trial data. Individual patient data from clinical trials is the raw material for meta-analyses, subgroup analyses, and post-market safety monitoring. Most of this data is proprietary. The European Medicines Agency has partially opened access to submission data for approved drugs. Full open access to de-identified patient-level trial data would transform secondary research capacity globally.

4. Open research protocols. Making research protocols available before trials begin allows independent researchers to identify design flaws, propose improvements, and plan complementary research. Pre-registration and open protocol publication are now standard expectations in many research fields and are being adopted in pharmaceutical research, but adoption is incomplete and inconsistent.

5. Open intellectual property in publicly funded research. The Bayh-Dole Act in the United States allowed universities to patent discoveries made with federal funding — a provision that transferred substantial public investment in basic research into private patent portfolios. A full open-access framework would require that publicly funded research results flow into a public domain, available for development by any manufacturer. This would require substantial redesign of how academic research is funded and incentivized.

The COVID-19 Test Case

The COVID-19 pandemic created an accelerated, partially visible test of several open-access principles. The mRNA vaccine platform developed at BioNTech and Moderna built on decades of publicly funded basic research — NIH investments in mRNA technology, DARPA funding for rapid vaccine development capabilities, and academic research at dozens of institutions. The Operation Warp Speed program in the United States provided over $10 billion in direct government funding to vaccine developers, alongside purchase guarantees that eliminated market risk.

The result was the fastest vaccine development in history. The open science elements — early publication of the SARS-CoV-2 genome by Chinese researchers, rapid pre-print publication of vaccine candidate results, international data sharing through the WHO — substantially accelerated the timeline.

But the IP framework remained proprietary. BioNTech and Moderna retained patents on the mRNA platform. They did not share manufacturing technology with developing-country producers. Covax, the international vaccine equity mechanism, was severely undersupplied because wealthy nations purchased the available supply directly and the manufacturers had no obligation to prioritize global distribution. The result was vaccine apartheid: by mid-2021, most high-income nations had vaccinated large fractions of their populations while most low-income nations had vaccinated less than 5 percent.

The proposal by India and South Africa at the WTO for a temporary waiver of vaccine IP rights was opposed by most high-income nations, led by the European Union and the United States (the Biden administration eventually supported a partial waiver, which was agreed in a substantially weakened form). The experience demonstrated both the feasibility of accelerated open-science research and the political barriers to open-access IP frameworks.

The Funding Problem

The most serious objection to full open-access pharmaceutical research is not proprietary in the narrow sense. It is a funding problem. If patents cannot generate returns sufficient to motivate private investment, and if public and philanthropic investment is insufficient to replace private investment, then the total volume of research declines.

This objection is empirically testable and the evidence is mixed. Direct assessment is difficult because the counterfactual — total public and philanthropic investment in a world without patent incentives — is not observable. But several proxies are available.

First, the software analogy. Open-source software, developed collaboratively without patent protection for the resulting code, has produced some of the most important computational infrastructure in existence: Linux, Apache, PostgreSQL, Python, Mozilla, Android. The total volume of software development has not collapsed in areas where open-source models prevail. This is not a perfect analogy — pharmaceutical research involves much higher direct costs per successful output than software development — but it demonstrates that open-access models can sustain very large, productive research communities.

Second, the prize model. Several economists, including Michael Kremer and Aidan Hollis, have proposed replacing patent exclusivity with prize mechanisms: the developer of a drug meeting defined efficacy and safety criteria receives a large public payment, in exchange for which the drug enters the public domain and is manufactured generically from the start. This model aligns incentives with medical need rather than market size, eliminates monopoly pricing, and provides comparable financial rewards to successful developers.

The Advanced Market Commitment mechanism, used to finance pneumococcal vaccines for developing countries, is a partial implementation of this logic: donors pre-committed to purchasing vaccines at a specified price, providing the market assurance that manufacturers needed to invest in development. The mechanism worked — pneumococcal vaccine coverage in low-income countries rose substantially. The prize model scales this logic to the full development cost.

Third, the public investment baseline. The National Institutes of Health invests approximately $45 billion annually in biomedical research. A significant fraction of commercially successful drugs trace their key mechanism discoveries to NIH-funded basic research — one systematic study found that 40 of 49 drugs approved by the FDA between 2010 and 2016 received NIH funding. The current system takes substantial public investment in basic research and requires the public to pay patent prices to access the resulting drugs. A system that maintained or increased public investment in the full development pipeline — not just basic research — would substantially expand the open-access research commons without relying entirely on philanthropic or prize mechanisms.

The Regulatory Reform Dimension

Open-access pharmaceutical research intersects with regulatory reform in ways that are often underappreciated. The FDA and its international equivalents are information-intensive institutions: they make approval decisions based on data submitted by applicants, and the quality of their decisions is limited by the quality and completeness of the submitted data.

Full open access to clinical trial data would transform regulatory capacity in two directions. First, it would allow independent researchers to conduct analyses that regulators currently cannot — post-hoc subgroup analyses, long-term outcome tracking, comparative effectiveness studies across trial populations. Second, it would allow regulators themselves to conduct more robust reviews, because the data available to them would be the full dataset rather than the company's curated submission.

The EMA's clinical trial transparency initiative, launched in 2016, represents the most advanced institutional step toward this model among major regulatory bodies. The EMA now publishes clinical reports submitted as part of marketing authorization applications — detailed documents running to thousands of pages that describe trial design, conduct, results, and analysis. The impact of this change on research quality is still being measured, but early evidence suggests it has identified errors and inconsistencies that would not have been detected under the prior opacity model.

The Civilizational Stakes

Antibiotic resistance is projected to kill 10 million people per year by 2050 if current trends continue — exceeding cancer mortality. The pharmaceutical industry has largely abandoned antibiotic development because the economics are incompatible with the patent model: antibiotics are used briefly, priced low to encourage appropriate use, and rapidly become obsolete as resistance develops. The return on antibiotic investment is structurally insufficient to attract private capital. This is a civilizational-scale market failure, and the patent system cannot solve it.

Pandemic preparedness offers a similar case. The COVID-19 experience demonstrated that the world can develop effective vaccines in under a year when sufficient public investment and open-science infrastructure are in place. The experience also demonstrated that without open IP frameworks and equitable distribution mechanisms, the resulting vaccines cannot reach the populations that most need them in the timeframes that epidemiology requires.

The pharmaceutical research system of the twenty-first century needs to solve problems that the patent system is structurally unsuited to address: neglected diseases, antibiotic resistance, pandemic preparedness, rare diseases with small markets, and treatments for conditions primarily affecting elderly populations in aging societies. These are not market failures in the sense of temporary distortions. They are the predictable output of a system that optimizes for patent returns on blockbuster drugs.

Full open access pharmaceutical research — combining mandatory data disclosure, public investment in full development pipelines, prize mechanisms, and open IP frameworks for publicly funded research — would not solve all of these problems. But it would restructure the information environment in which pharmaceutical research occurs, eliminate the selective disclosure that currently corrupts the evidence base, and redirect research capacity toward the medical needs that markets cannot and will not address. In a domain where wrong information costs lives, the revision from opacity to transparency may be the most consequential institutional change medicine can make.